FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer

Laura Evangelista, Stefania Redana, Manuela Racca, Elena Geuna, Lorenzo Vinante, Giulia Zago, Valentina De Carolis, Cristina Ghiotto, Giorgio Saladini, Teresio Varetto

Research output: Contribution to journalArticle

Abstract

BACKGROUND: We aim to retrospectively evaluate the impact of hormone therapy (HT) on FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. PATIENTS AND METHODS: Three hundred eight patients with BC were scanned with PET/CT at 2 Italian institutions (mean time from diagnosis 4 yrs, range: 1-24 yrs). Main indications for PET/CT were elevation of tumor markers (34.4%) and clinical or radiological suspicion of relapse (65.6%). The diagnostic accuracy of FDG PET/CT was computed according to the standard method. Student t test was used to assess the mean differences between the study groups, whereas categorical data were compared with chi-square test. Significance was set at P

Original languageEnglish
JournalClinical Nuclear Medicine
Volume39
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • breast cancer
  • diagnostic accuracy
  • FDG PET/CT
  • hormone therapy
  • recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer'. Together they form a unique fingerprint.

  • Cite this